AZD 5363

Drug Profile

AZD 5363

Alternative Names: AZD5363

Latest Information Update: 16 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astex Therapeutics; Cancer Research Technology; The Institute of Cancer Research
  • Developer Astex Therapeutics; AstraZeneca; Cancer Research Technology; Conquer Cancer Foundation; Netherlands Cancer Institute; Royal Marsden NHS Foundation Trust; Samsung Medical Center; The Institute of Cancer Research; University of Nottingham; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Prostate cancer
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 28 Feb 2018 AstraZeneca completes the phase I/II BEECH trial in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease) in Bulgaria, Canada, the Czech Republic, France, Japan, Mexico, Peru, Singapore, South Korea, Spain and United Kingdom (NCT01625286) (JapicCTI-142468) (EudraCT2011-006312-31)
  • 16 Jan 2018 Phase I development for Solid tumours (Late-stage disease, Second-line therapy or greater) is ongoing in United Kingdom, Spain, Italy, France, Canada, Netherlands, Japan, Denmark, Sweden and USA (NCT01226316)
  • 05 Dec 2017 Adverse events and efficacy data from a phase I trial in Solid tumours presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top